{"i": ["Bevacizumab", "pentostatin and cyclophosphamide .", "rituximab", "cyclophosphamide", "chemotherapy", "sulfamethoxazole - trimethoprim or alternative ) and herpes zoster ( valacyclovir or alternative )", "pentostatin", "CIT", "PCR in combination with bevacizumab", "bevacizumab", "anti - VEGF therapy", "pentostatin , cyclophosphamide and rituximab ( PCR )", "PCR alone", "Ibrutinib or Idelalisib", "ibrutinib or Idelalisib", "bevacizumab ( PCR - B )", "chemoimmunotherapy", "allopurinol", "FCR", "PCR", "PCR in combination with bevacizumab ( PCR - B", "bevacizumab .", "anti - VEGF antibody", "chemoimmunotherapy ( CIT )", "Pegfilgrastim", "PCR - B", "pentostatin , cyclophosphamide , and rituximab with ( PCR )", "anti - VEGF agent , bevacizumab ( PCR - B ), or without bevacizumab ( PCR )", "anti - VEGF"], "o": ["rate of grade 3 - 4 cardiovascular toxicity", "dose delay", "CR or CR with incomplete marrow recovery ( CR - i", "hematologic toxicity .", "CR rates", "median PFS and TFS", "baseline CCL - 3 plasma levels", "grade 3 + event", "complications", "baseline CCL - 3 levels", "cytokine plasma levels and responses", "CRs or PRs", "hypertension , need for polypectomy , and proteinuria", "Median levels of VEGF , b - FGF , TSP - 1 , CCL - 3 and CCL - 4", "Treatment - free survival ( TFS )", "cardiovascular toxicity .", "pneumonia , nausea , neurological symptoms , and treating physician choice .", "CCL - 4 levels", "nodular partial remission", "Thrombocytopenia", "renal and hepatic function", "CCL - 3 and CCL - 4", "rate of complete response .", "CR", "progression - free and treatment - free survival", "adverse events", "Toxicity", "response rates", "disease - free survival", "Median TFS", "response", "CCL - 3 , CCL - 4 , TSP - 1 and / or b - FGF", "treatment free survival", "complete remission rate", "MRD eradication rate", "Platelet and hemoglobin adverse events", "Median OS", "Neutropenia", "ECOG performance status", "cardiovascular toxicities", "complete response ( CR", "VEGF ( isoform 165 ), b - FGF , CCL - 3 and CCL - 4", "cardiovascular toxicity", "grade 4 + event", "treatment - free survival ( TFS )(", "PFS and TFS .", "VEGF , b - FGF , anti -[ thrombospondin ( TSP )- 1 ], chemokine ligand ( CCL )- 3", "achievement of CR", "efficacy", "TFS", "PFS and TFS", "response rate", "VEGF levels", "CCL - 3 and CCL - 4 levels", "febrile neutropenia", "PFS", "time to event", "complete remission ( CR ) rate", "non - fatal cardiovascular complications", "progression - free survival ( PFS )(", "Cardiovascular toxicity", "hypertensive emergency", "plasma levels", "Plasma cytokine kinetics", "cytokine values", "Progression - free survival ( PFS )", "overall survival", "Hemoglobin decrease", "MRD - negative remission", "severe adverse events", "median PFS", "residual disease", "CD38 , ZAP - 70 , IGHV mutation status , and recurrent cytogenetic abnormalities", "3 + toxicity", "13q14", "clinical activity", "central nervous system hemorrhage .", "CCL - 3 levels", "Non - heme toxicity", "hypertension , congestive heart failure , and arterial and venous thromboembolic disease .", "complete response rates", "patient choice , infectious complication ( pneumonia ) and cardiovascular complications ( hypertension , myocardial ischemia , congestive heart failure , and aortic dissection );", "myocarditis", "hypertension", "complete remission ( CR", "Overall survival ( OS )", "CR / CR - i", "left ventricular failure", "left ventricular dysfunction", "achievement of CR / CR - i or MRD eradication", "baseline values of CCL - 3", "rate of MRD negative remissions", "Grade 3 + Heme toxicity", "Grade 3 - 4 cardiovascular toxicity", "torsade", "cardiovascular complication", "CHF"]}